Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosuvastatin-based combination therapy for coronary plaque progression in coronary artery disease
ACTRN12611000394943Phase 4Not yet recruiting
- Sponsor
- Peking University Health Science Center
- Start
- May 2011
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of rosuvastatin, fenofibrate and metoprolol in coronary arteriosclerosis and hyperlipidemia (4 arms), sponsored by Peking University Health Science Center. Primary endpoints: Change in atheroma plaque volume, Change in CT attenuation value and 1 more. Planned start May 2011; status: not yet recruiting.
02
Drugs
rosuvastatinfenofibratemetoprolol
03
Conditions
coronary arteriosclerosishyperlipidemia
Beyond the preview
Go deeper on ACTRN12611000394943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000394943.